The use of blood biomarkers in precision medicine for the primary prevention of atherosclerotic cardiovascular disease: a review

References

• Mensah GA, Wei GS, Sorlie PD, et al. Decline in cardiovascular mortality: possible causes and implications. Circ Res. 2017;120(2):366–380.
   PubMed Web of Science ®Google Scholar
• Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American heart association. Circulation. 2020;141(9):e139–e596.
   PubMed Web of Science ®Google Scholar
• Woolf SH, Chapman DA, Lee JH. COVID-19 as the leading cause of death in the United States. JAMA. 2021;325(2):123–124.
   PubMed Web of Science ®Google Scholar
• Roth GA, Forouzanfar MH, Moran AE, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015;372(14):1333–1341.
   PubMed Web of Science ®Google Scholar
• Sidney S, Quesenberry CP Jr., Jaffe MG, et al. Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiol. 2016;1(5):594–599.
   PubMed Web of Science ®Google Scholar
• Curtin SC. Trends in cancer and heart disease death rates among adults aged 45–64: United States, 1999–2017. Natl Vital Stat Rep. 2019;68(6):1–8.
   PubMedGoogle Scholar
• Jameson JL, Longo DL. Precision medicine–personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229–2234.
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al., ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e563–e595.
   PubMed Web of Science ®Google Scholar
• Amin NP, Martin SS, Blaha MJ, et al. Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines. J Am Coll Cardiol. 2014;63:2789–2794.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American heart association and American college of cardiology. J Am Coll Cardiol 2019;73:3153–3167.
   Google Scholar
• McEvoy JW, Diamond GA, Detrano RC, et al. Risk and the physics of clinical prediction. Am J Cardiol. 2014;113:1429–1435.
   PubMed Web of Science ®Google Scholar
• Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475–1482.
   PubMed Web of Science ®Google Scholar
• Yang X, Li J, Hu D, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR project (prediction for ASCVD risk in China). Circulation. 2016;134(19):1430–1440.
   PubMed Web of Science ®Google Scholar
• Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010 Nov;5(6):463–466.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease–six year follow-up experience. The Framingham study. Ann Intern Med. 1961;55:33–50.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from. 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Emberson J, Blackwell L, Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from. 27 randomised trials. Lancet. 2012;380(9841):581–590.
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al., Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38(32):2459–2472.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al., 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;139(25):e1046–e1081.
   PubMed Web of Science ®Google Scholar
• Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381(16):1557–1567.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
   PubMed Web of Science ®Google Scholar
• Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310(19):2061–2068.
   PubMed Web of Science ®Google Scholar
• Martin SS, Giugliano RP, Murphy SA, et al. Comparison of low-density lipoprotein cholesterol assessment by martin/hopkins estimation, friedewald estimation, and preparative ultracentrifugation: insights from the FOURIER trial. JAMA Cardiol. 2018;3(8):749–753.
   PubMed Web of Science ®Google Scholar
• Quispe R, Hendrani A, Elshazly MB, et al. Accuracy of low-density lipoprotein cholesterol estimation at very low levels. BMC Med. 2017;15(1):83.
   PubMedGoogle Scholar
• Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis. 1996;124(Suppl):S1–9.
   PubMedGoogle Scholar
• Kathiresan S, Otvos JD, Sullivan LM, et al., Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham heart study. Circulation. 2006;113(1):20–29.
   PubMed Web of Science ®Google Scholar
• Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014;129(5):553–561.
   PubMed Web of Science ®Google Scholar
• Martin SS, Michos ED, Martin SS, et al. Are we moving towards concordance on the principle that lipid discordance matters? Circulation. 2014;129(5):539–541.
   PubMed Web of Science ®Google Scholar
• Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol. 2006;17(4):412–417.
   PubMed Web of Science ®Google Scholar
• Cromwell WC, Otvos JD, Keyes MJ, et al., LDL particle number and risk of future cardiovascular disease in the Framingham offspring study - implications for LDL management. J Clin Lipidol. 2007;1(6):583–592.
   PubMed Web of Science ®Google Scholar
• Sniderman AD. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. J Clin Lipidol. 2008;2(1):36–42.
   PubMed Web of Science ®Google Scholar
• Otvos JD, Mora S, Shalaurova I, et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5(2):105–113.
   PubMed Web of Science ®Google Scholar
• Sharman MJ, Kraemer WJ, Love DM, et al. A ketogenic diet favorably affects serum biomarkers for cardiovascular disease in normal-weight men. J Nutr. 2002;132(7):1879–1885.
   PubMed Web of Science ®Google Scholar
• Westman EC, Yancy WS Jr., Olsen MK, et al. Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses. Int J Cardiol. 2006;110(2):212–216.
   PubMed Web of Science ®Google Scholar
• Shapiro MD, Apolipoprotein FS. B-containing lipoproteins and atherosclerotic cardiovascular disease. F1000Res. 2017;6:134.
   PubMedGoogle Scholar
• Ference BA, Kastelein JJP, Ginsberg HN, et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA. 2017;318(10):947–956.
   PubMed Web of Science ®Google Scholar
• Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364–373.
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Pencina M. ApoB. Circ Res. 2019;124(10):1425–1427.
   PubMedGoogle Scholar
• Pallazola VA, Sathiyakumar V, Park J, et al. Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia). Arch Med Sci. 2020;16(5):993–1003.
   PubMed Web of Science ®Google Scholar
• Sathiyakumar V, Pallazola VA, Park J, et al. Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the very large database of lipids and national health and nutrition examination survey. Arch Med Sci. 2020;16(6):1279–1287.
   PubMed Web of Science ®Google Scholar
• Contois JH, Apolipoprotein DV. B measurement: need for standardization. J Clin Lipidol. 2018;12(2):264–265.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853.
   PubMed Web of Science ®Google Scholar
• Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood. 2001;98(10):2980–2987.
   PubMed Web of Science ®Google Scholar
• Von Depka M, Nowak-Gottl U, Eisert R, et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood. 2000;96(10):3364–3368.
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Gorby LK, Stroes ES, et al. Lipoprotein(a) and its potential association with thrombosis and inflammation in COVID-19: a testable hypothesis. Curr Atheroscler Rep. 2020;22(9):48.
   Google Scholar
• Schmidt K, Noureen A, Kronenberg F, et al. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57(8):1339–1359.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Gordts P, Nora C, et al. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275–2284.
   PubMed Web of Science ®Google Scholar
• Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102(10):1082–1085.
   PubMed Web of Science ®Google Scholar
• Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–423.
   PubMed Web of Science ®Google Scholar
• Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke. 2007;38(6):1959–1966.
   PubMed Web of Science ®Google Scholar
• Nave AH, Lange KS, Leonards CO, et al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis. 2015;242(2):496–503.
   PubMed Web of Science ®Google Scholar
• Virani SS, Brautbar A, Davis BC, et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the atherosclerosis risk in communities (ARIC) study. Circulation. 2012;125(2):241–249.
   PubMed Web of Science ®Google Scholar
• Aronis KN, Zhao D, Hoogeveen RC, et al. Associations of lipoprotein(a) levels with incident atrial fibrillation and ischemic stroke: the ARIC (atherosclerosis risk in communities) study. J Am Heart Assoc. 2017;6:12.
   Web of Science ®Google Scholar
• Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503–512.
   PubMed Web of Science ®Google Scholar
• Makshood M, Joshi PH, Kanaya AM, et al. Lipoprotein (a) and aortic valve calcium in South Asians compared to other race/ethnic groups. Atherosclerosis. 2020;313:14–19.
   PubMed Web of Science ®Google Scholar
• Albers JJ, Slee A, O’Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglyceride and impact on global health outcomes). J Am Coll Cardiol. 2013;62:1575–1579.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483–1492.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation. 2020;141(20):1608–1617.
   PubMed Web of Science ®Google Scholar
• Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb. 1992;12(10):1214–1226.
   PubMedGoogle Scholar
• Sandholzer C, Boerwinkle E, Saha N, et al. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest. 1992;89(3):1040–1046.
   PubMed Web of Science ®Google Scholar
• Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64:851–860.
   PubMed Web of Science ®Google Scholar
• Triglycerides BM. Triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118(1):138–145.
   PubMed Web of Science ®Google Scholar
• Boullart AC, De Graaf J, Stalenhoef AF. Serum triglycerides and risk of cardiovascular disease. Biochim Biophys Acta. 2012;1821(5):867–875.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017;14(7):401.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.
   PubMed Web of Science ®Google Scholar
• Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724–730.
   PubMed Web of Science ®Google Scholar
• Garg A, Sharma A, Krishnamoorthy P, et al. Role of Niacin in Current Clinical Practice: a Systematic Review. Am J Med. 2017;130(2):173–187.
   PubMed Web of Science ®Google Scholar
• Jakob T, Nordmann AJ, Schandelmaier S, et al. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 2016;11:CD009753.
   PubMedGoogle Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11–22.
   PubMed Web of Science ®Google Scholar
• ASCEND Group, Bowman L, Mafham M, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540–1550.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Lincoff AM, Garcia M, et al., Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268–2280.
   PubMed Web of Science ®Google Scholar
• Orringer CE, Jacobson TA, Maki KC. National lipid association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019;13(6):860–872.
   PubMed Web of Science ®Google Scholar
• Gaze DC, Collinson PO. Multiple molecular forms of circulating cardiac troponin: analytical and clinical significance. Ann Clin Biochem. 2008;45(Pt 4):349–355.
   PubMedGoogle Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–e228.
   PubMed Web of Science ®Google Scholar
• Park KC, Gaze DC, Collinson PO, et al. Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc Res. 2017(113):1708–1718
   Google Scholar
• Apple FS, Collinson PO, Task IFCC. Force on clinical applications of cardiac bio-markers. analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58(1):54–61.
   PubMed Web of Science ®Google Scholar
• Martin Raymondi D, Garcia H, Alvarez I, et al. TUSARC: prognostic value of high-sensitivity cardiac troponin T assay in asymptomatic patients with high cardiovascular risk. Am J Med. 2019;132(5):631–638.
   PubMed Web of Science ®Google Scholar
• Jia X, Sun W, Hoogeveen RC, et al., High-sensitivity troponin i and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study. Circulation. 2019;139(23):2642–2653.
   PubMed Web of Science ®Google Scholar
• Ford I, Shah AS, Zhang R, et al. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol. 2016;68(25):2719–2728.
   PubMed Web of Science ®Google Scholar
• Lan NSR, Bell DA, McCaul KA, et al. High-sensitivity cardiac troponin I improves cardiovascular risk prediction in older men: HIMS (the health in men study). J Am Heart Assoc. 2019;8:e011818.
   PubMed Web of Science ®Google Scholar
• Diris JH, Hackeng CM, Kooman JP, et al. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation. 2004;109(1):23–25.
   PubMed Web of Science ®Google Scholar
• Michos ED, Wilson LM, Yeh HC, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-analysis. Ann Intern Med. 2014 Oct 7;161(7):491–501.
   PubMed Web of Science ®Google Scholar
• Ebong IA, Wilson MD, Bertoni AG, et al. High-sensitivity cardiac troponin T and the risk of heart failure in postmenopausal women of the ARIC Study. Menopause. 2021 Jan 4;28(3):284–291.
   PubMed Web of Science ®Google Scholar
• Sandoval Y, Bielinski SJ, Daniels LB, et al. Atherosclerotic cardiovascular disease risk stratification based on measurements of troponin and coronary artery calcium. J Am Coll Cardiol. 2020;76(4):357–370.
   PubMed Web of Science ®Google Scholar
• Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357–2368.
   PubMed Web of Science ®Google Scholar
• Goetze JP, Mogelvang R, Maage L, et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J. 2006;27(24):3004–3010.
   PubMed Web of Science ®Google Scholar
• Nadir MA, Rekhraj S, Wei L, et al. Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol. 2012;60:960–968.
   PubMed Web of Science ®Google Scholar
• Rana BS, Davies JI, Band MM, et al. B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes. Heart. 2006;92(7):916–920.
   PubMed Web of Science ®Google Scholar
• Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 2002;288(10):1252–1259.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350(7):655–663.
   PubMed Web of Science ®Google Scholar
• Nambi V, Liu X, Chambless LE, et al. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk–the atherosclerosis risk in communities study. Clin Chem. 2013;59(12):1802–1810.
   PubMed Web of Science ®Google Scholar
• Linssen GC, Bakker SJ, Voors AA, et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J. 2010;31(1):120–127.
   PubMed Web of Science ®Google Scholar
• Marz W, Tiran B, Seelhorst U, et al. N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen risk and cardiovascular health study. Clin Chem. 2007;53:1075–1083.
   PubMed Web of Science ®Google Scholar
• Alfaddagh A, Martin SS, Leucker TM, et al. Inflammation and cardiovascular disease: from mechanisms to therapeutics. Am J Prev Cardiol. 2020;4:100130.
   PubMedGoogle Scholar
• Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol. 2017;70(18):2278–2289.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al., Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131.
   PubMed Web of Science ®Google Scholar
• Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279(47):48487–48490.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843.
   PubMed Web of Science ®Google Scholar
• Quispe R, Michos ED, Martin SS, et al. High-sensitivity C-reactive protein discordance with atherogenic lipid measures and incidence of atherosclerotic cardiovascular disease in primary prevention: the ARIC study. J Am Heart Assoc. 2020;9(3):e013600.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N, et al., Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297(6):611–619.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men. Circulation. 2008;118(22):2243–2251, 4p following 2251.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al., Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175–1182.
   PubMed Web of Science ®Google Scholar
• Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132(13):1224–1233.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–28.
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319–328.
   PubMed Web of Science ®Google Scholar
• Michos ED, Martin SS, Blumenthal RS. Bringing back targets to “IMPROVE” atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one? Circulation. 2015;132(13):1218–1220.
   PubMed Web of Science ®Google Scholar
• Michos ED, Blumenthal RS. Treatment concentration of high-sensitivity C-reactive protein. Lancet. 2018;391(10118):287–289.
   PubMed Web of Science ®Google Scholar
• Cardoso R, Kaul S, Okada DR, et al. A deeper dive into the CANTOS “responders” substudy. Mayo Clin Proc. 2018;93(7):830–833.
   PubMed Web of Science ®Google Scholar
• Otvos JD, Shalaurova I, Wolak-Dinsmore J, et al. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem. 2015;61(5):714–723.
   PubMed Web of Science ®Google Scholar
• Benson EA, Tibuakuu M, Zhao D, et al. Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: the multi-ethnic study of atherosclerosis. Clin Cardiol. 2018;41(11):1439–1445.
   PubMed Web of Science ®Google Scholar
• Akinkuolie AO, Buring JE, Ridker PM, et al. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc. 2014;3:e001221.
   PubMed Web of Science ®Google Scholar
• Lawler PR, Akinkuolie AO, Chandler PD, et al. Circulating N-linked glycoprotein acetyls and longitudinal mortality risk. Circ Res. 2016;118(7):1106–1115.
   PubMed Web of Science ®Google Scholar
• Duprez DA, Otvos J, Sanchez OA, et al. Comparison of the predictive value of GlycA and other biomarkers of inflammation for total death, incident cardiovascular events, noncardiovascular and noncancer inflammatory-related events, and total cancer events. Clin Chem. 2016;62(7):1020–1031.
   PubMed Web of Science ®Google Scholar
• Fashanu OE, Oyenuga AO, Zhao D, et al. GlycA, a novel inflammatory marker and its association with peripheral arterial disease and carotid plaque: the multi-ethnic study of atherosclerosis. Angiology. 2019;70(8):737–746.
   PubMed Web of Science ®Google Scholar
• Tibuakuu M, Fashanu OE, Zhao D, et al. GlycA, a novel inflammatory marker, is associated with subclinical coronary disease. AIDS. 2019;33(3):547–557.
   PubMed Web of Science ®Google Scholar
• Ezeigwe A, Fashanu OE, Zhao D, et al. The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: the multi-ethnic study of atherosclerosis. Atherosclerosis. 2019;282:91–99.
   PubMed Web of Science ®Google Scholar
• Jang S, Ogunmoroti O, Ndumele CE, et al. Association of the novel inflammatory marker GlycA and incident heart failure and its subtypes of preserved and reduced ejection fraction: the multi-ethnic study of atherosclerosis. Circ Heart Fail. 2020;13(8):e007067.
   PubMed Web of Science ®Google Scholar
• Burke JE, Dennis EA. Phospholipase A2 biochemistry. Cardiovasc Drugs Ther. 2009;23(1):49–59.
   PubMed Web of Science ®Google Scholar
• MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338(Pt 2):479–487.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Circulation. 2004;109(7):837–842.
   PubMed Web of Science ®Google Scholar
• Tibuakuu M, Kianoush S, DeFilippis AP, et al. Usefulness of lipoprotein-associated phospholipase A2 Activity and C-reactive protein in identifying high-risk smokers for atherosclerotic cardiovascular disease (from the atherosclerosis risk in communities study). Am J Cardiol. 2018;121:1056–1064.
   PubMed Web of Science ®Google Scholar
• Investigators STABILITY, White HD, Held C, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702–1711.
   PubMed Web of Science ®Google Scholar
• Li S, Shin HJ, Ding EL. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302(2):179–188.
   PubMed Web of Science ®Google Scholar
• D’Souza AM, Neumann UH, Glavas MM, et al. The glucoregulatory actions of leptin. Mol Metab. 2017;6(9):1052–1065.
   PubMed Web of Science ®Google Scholar
• Hsu W-YW-Y, Chao Y-WY-W, Tsai Y-LY-L, et al. Resistin induces monocyte-endothelial cell adhesion by increasing ICAM-1 and VCAM-1 expression in endothelial cells via p38MAPK-dependent pathway. J Cell Physiol. 2011;226(8):2181–2188.
   PubMed Web of Science ®Google Scholar
• Unamuno X, Gomez-Ambrosi J, Rodriguez A, et al. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur J Clin Invest. 2018;48(9):e12997.
   PubMed Web of Science ®Google Scholar
• Landecho MF, Tuero C, Valenti V, et al. Relevance of leptin and other adipokines in obesity-associated cardiovascular risk. Nutrients. 2019;11:11.
   Web of Science ®Google Scholar
• Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol. 2008;52(15):1201–1210.
   PubMed Web of Science ®Google Scholar
• Acquarone E, Monacelli F, Borghi R, et al. Resistin: a reappraisal. Mech Ageing Dev. 2019;178:46–63.
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Lowe GD, Rumley A, et al. Adipokines and risk of type 2 diabetes in older men. Diabetes Care. 2007;30(5):1200–1205.
   PubMed Web of Science ®Google Scholar
• Muse ED, Feldman DI, Blaha MJ, et al. The association of resistin with cardiovascular disease in the multi-ethnic study of atherosclerosis. Atherosclerosis. 2015;239(1):101–108.
   PubMed Web of Science ®Google Scholar
• Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291(14):1730–1737.
   PubMed Web of Science ®Google Scholar
• Martin SS, Blaha MJ, Muse ED, et al. Leptin and incident cardiovascular disease: the Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2015;239(1):67–72.
   PubMed Web of Science ®Google Scholar
• Havranek EP, Mujahid MS, Barr DA, et al., Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American heart association. Circulation. 2015;132(9):873–898.
   PubMed Web of Science ®Google Scholar
• Yeboah J, McClelland RL, Polonsky TS, et al., Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308(8):788–795.
   PubMed Web of Science ®Google Scholar
• Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol. 2016;67(2):139–147.
   PubMed Web of Science ®Google Scholar
• Pender A, Lloyd-Jones DM, Stone NJ, et al. Refining statin prescribing in lower-risk individuals: informing risk/benefit decisions. J Am Coll Cardiol. 2016;68:1690–1697
   PubMed Web of Science ®Google Scholar
• Kambhampati S, Ashvetiya T, Stone NJ, et al., Shared decision-making and patient empowerment in preventive cardiology. Curr Cardiol Rep. 2016;18(5):49.
   PubMed Web of Science ®Google Scholar